COCH

Envoy Medical Inc

Add to Watchlist

Advanced Chart

1.530

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.530

Open

1.530

VWAP

1.53

Vol

1.63K

Mkt Cap

32.93M

Low

1.530

Amount

2.49K

EV/EBITDA(TTM)

Total Shares

19.60M

55.57M

EV/OCF(TTM)

P/S(TTM)

137.32

Envoy Medical, Inc. is a hearing health company. The Company is engaged in providing medical technologies across the hearing loss spectrum, all designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they require. Its hearing solutions include hearing aids, middle ear implants, bone conduction devices and cochlear implants. The bone conduction hearing device has two components: an external component and a surgically implanted fixture placed in the bone behind the ear. Its bone conduction hearing device offers amplification without ear mold in the ear. Its hearing aids are devices that amplify sound for those with mild to moderate hearing loss. Its Esteem is a fully implanted active middle ear implant designed to improve the hearing of adults diagnosed with moderate to severe sensorineural hearing loss. Cochlear implants are a solution for people with moderate-to-profound sensorineural hearing loss.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

50.00K

+8.7%

-0.300

+3.45%

80.00K

+90.48%

-0.330

-28.26%

80.00K

+42.86%

-0.307

-17.12%

Estimates Revision

The market is revising Upward the revenue expectations for Envoy Medical, Inc. (COCH) for FY2025, with the revenue forecasts being adjusted by 5.81% over the past three months. During the same period, the stock price has changed by -8.45%.

Revenue Estimates for FY2025

Revise Upward

+5.81%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.18%

In Past 3 Month

Stock Price

Go Down

-8.45%

In Past 3 Month

2 Analyst Rating

406.54% Upside

Wall Street analysts forecast COCH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCH is 7.75 USD with a low forecast of 6.00 USD and a high forecast of 9.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

406.54% Upside

Current: 1.530

Low

6.00

Averages

7.75

High

9.50

406.54% Upside

Current: 1.530

Low

6.00

Averages

7.75

High

9.50

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$9 → $9.25

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$9 → $9.25

2025-04-21

Maintains

Strong Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$8.75 → $9

2024-12-06

Reason

Ascendiant Capital

Edward Woo

Price Target

$8.75 → $9

2024-12-06

Maintains

Strong Buy

Reason

Brookline Capital

Tyler Bussian

Strong Buy

Initiates

2024-10-14

Reason

Brookline Capital

Tyler Bussian

Price Target

2024-10-14

Initiates

Strong Buy

Reason

Brookline analyst Tyler Bussian initiated coverage of Envoy Medical with a Buy rating and $9 price target.

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$8.5 → $8.75

2024-09-03

Reason

Ascendiant Capital

Edward Woo

Price Target

$8.5 → $8.75

2024-09-03

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Envoy Medical Inc (COCH.O) is -1.24, compared to its 5-year average forward P/E of -1.95. For a more detailed relative valuation and DCF analysis to assess Envoy Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.95

Current PE

-1.24

Overvalued PE

-0.25

Undervalued PE

-3.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.43

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.70

Undervalued EV/EBITDA

-3.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

105.24

Current PS

122.77

Overvalued PS

205.70

Undervalued PS

4.78

Financials

Annual

Quarterly

FY2025Q2

YoY :

+14.71%

78.00K

Total Revenue

FY2025Q2

YoY :

+4.49%

-5.07M

Operating Profit

FY2025Q2

YoY :

+44.16%

-5.69M

Net Income after Tax

FY2025Q2

YoY :

+10.34%

-0.32

EPS - Diluted

FY2025Q2

YoY :

-10.83%

-4.46M

Free Cash Flow

FY2025Q2

YoY :

-23.16%

-200.00

Gross Profit Margin - %

FY2025Q2

YoY :

+5.64%

-7.45K

FCF Margin - %

FY2025Q2

YoY :

+25.68%

-7.29K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

14.6K

USD

Months

3-6

82.4K

USD

Months

6-9

0.0

USD

Months

0-12

22.2K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

14.6K

USD

Months

3-6

82.4K

USD

Months

6-9

0.0

USD

Months

0-12

22.2K

USD

Months

COCH News & Events

Events Timeline

2024-11-14 (ET)

2024-11-14

07:42:28

Envoy Medical reports Q3 EPS (37c) vs. 13c last year.

2024-11-01 (ET)

2024-11-01

08:05:27

Envoy Medical receives FDA approval to initiate study for hearing device

2024-10-24 (ET)

2024-10-24

08:27:06

Envoy Medical supports ITEM Coalition letter to CMS on hearing devices

News

1.0

06-13Newsfilter

Life Sciences Investor Forum: Now Available for Online Viewing

1.0

06-11Globenewswire

Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th

1.0

06-10Newsfilter

Life Sciences Investor Forum Agenda Announced for June 11th-12th

People Also Watch

Hub Cyber Security Ltd

Cognition Therapeutics Inc

Haverty Furniture Companies Inc

Citius Pharmaceuticals Inc

Foxx Development Holdings Inc

6.450

USD

+3.37%

FAQ

What is Envoy Medical Inc (COCH) stock price today?

The current price of COCH is 1.53 USD — it has increased 0 % in the last trading day.

COCH

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

COCH News & Events

Events Timeline

News

People Also Watch

FAQ

What is Envoy Medical Inc (COCH) stock price today?

What is Envoy Medical Inc (COCH)'s business?

What is the price predicton of COCH Stock?

What is Envoy Medical Inc (COCH)'s revenue for the last quarter?

What is Envoy Medical Inc (COCH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Envoy Medical Inc (COCH)'s fundamentals?

How many employees does Envoy Medical Inc (COCH). have?

What is Envoy Medical Inc (COCH) market cap?